tirzepatide insulin Shifting the Scales: Tirzepatide's Breakthrough in Obesity Management Tirzepatide approved for weight loss

"Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs." Ann Rheum Dis

BPC-157 is a research peptide and is not FDA-approved for human use

Effective January 1, 2025, Independence Blue Cross (IBX) will no longer offer coverage for drugs including glucagon-like peptide-1 receptor antagonist (GLP-1) and non-glucagon-like peptide-1 receptor antagonist (non-GLP-1) indicated for and prescribed solely for weight loss in the absence of other FDA-approved clinical indications

The supplement may improve thinking skills and lower your risk for Alzheimer's disease Better immunity

March Event: Motion for Leadership Structure Date: March 23, 2024 Notes: Lawyers for the plaintiffs submitted a motion for leadership structure to the court